no weight loss 2 weeks semaglutide 10 Reasons You Are NOT

Tirzepatide , a GLP-1/GIP receptor dual agonist developed by Eli Lilly, and survodutide , a Glucagon and GLP-1 receptor dual agonist developed jointly by Boehringer Ingelheim and Zealand Pharma, both obtained preliminary positive results in Phase 2 clinical trials for treating NASH in February of 2024

The injectable medications mimic a hormone made in the gut called glucagon-like peptide-1 (GLP-1), which helps manage blood sugar, reduce appetite and slow stomach emptying so you feel fuller, longer

This difference in absorption speed can impact how quickly you feel the medications effects, which is important for consistent results

Keep the medication in its original container, store it in a refrigerator until youre ready for use and keep it out of reach of children

Combination drug therapy was introduced as a way to surpass the weight loss barrier of a single medication (Gautron et al., 2015